INNATE PHARMA SP.ADR/1 (IDDA) — Long-term Investment Intensity
INNATE PHARMA SP.ADR/1 (IDDA) has a Long-term Investment Intensity of 16.7% as of December 2025. Long-term investments of €10.46 Million represent 16.7% of total assets of €62.72 Million. A higher ratio indicates a company with significant capital committed to long-duration strategic positions. Explore IDDA cash flow metrics to assess how effectively this company generates cash.
LT Investment Intensity
Long-term Investments
Total Assets
Country
INNATE PHARMA SP.ADR/1 Long-term Investment Intensity (2021–2025)
This chart shows how INNATE PHARMA SP.ADR/1's Long-term Investment Intensity has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the intensity stands at 16.7%, reflecting long-term investments of €10.46 Million against total assets of €62.72 Million EUR. Explore IDDA operating cash flow to total debt to assess how comfortably operating cash covers total debt obligations.
Annual Long-term Investment Intensity for INNATE PHARMA SP.ADR/1 (2021–2025)
The table below presents the year-by-year Long-term Investment Intensity for INNATE PHARMA SP.ADR/1 from 2021 to 2025, covering 5 annual filings. Each row shows total assets, long-term investments, the intensity percentage, and the change in percentage points compared to the prior year. For market capitalisation and broader financial context, see IDDA stock market capitalisation.
| Year | LT Investment Intensity | LT Investments (EUR) | Total Assets | Change (pp) |
|---|---|---|---|---|
| 2025 | 16.7% | €10.46 Million | €62.72 Million | ▲ +7.4 pp |
| 2024 | 9.3% | €10.28 Million | €111.06 Million | ▲ +3.7 pp |
| 2023 | 5.6% | €9.80 Million | €175.19 Million | ▼ -12.0 pp |
| 2022 | 17.6% | €35.12 Million | €199.29 Million | ▲ +2.7 pp |
| 2021 | 14.9% | €39.88 Million | €267.50 Million | — |